REGiMMUNE Presented Positive Results of RGI-2001 in the Reduction of Acute GvHD from Phase 2b Study at the 2022 ASH annual meeting
RGI-2001 was well tolerated and associated with a meaningful reduction [...]
REGiMMUNE to Present Results from the Phase 2b Study of RGI-2001 at the 2022 ASH Annual Meeting
TAIPEI, November 3, 2022 – REGiMMUNE Limited, a clinical-stage biopharmaceutical [...]
REGiMMUNE Appoints Charlie Hsu as CFO
Taipei, 16 May 2022 – REGiMMUNE Limited, a biopharmaceutical company [...]
REGiMMUNE presented at the ASH annual meeting on 5 December 2020
REGiMMUNE Corporation has presented clinical data on RGI-2001 Intravenous [...]